GLPwatch
Adlyxin for Chronic kidney disease
lixisenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCAdlyxin (lixisenatide) is not FDA-approved for chronic kidney disease, and any use for this condition is off-label or investigational. The listed research explores lixisenatide’s effects on kidney outcomes in diabetes or animal models but does not establish efficacy for treating chronic kidney disease.
AI summary of the sources below.
| Drug | Adlyxin (lixisenatide) |
|---|---|
| Condition | Chronic kidney disease |
| Approval status | Investigational / off-label |
| Research papers | 7 |
Adlyxin is not FDA-approved for chronic kidney disease; the research below reflects investigational or off-label study only.
Research on lixisenatide for chronic kidney disease (7)
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
- Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus.
- Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats.
- Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
- Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment.
- Potential roles for eNOS and NrF₂ /HO-1 signaling in the ameliorative effect of lixisenatide on diabetes-induced kidney injury in rats and its amplification by ticagrelor co-administration.
- Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial.